Skip to content

ImmunityBio, Inc.

IBRX

CIK 0001326110

← back to feed
Revenue (TTM)
$119.21M
+668.3% YoY Q1 May 2026
Net Income (TTM)
−$922.24M
+15.0% YoY Q1 May 2026
EPS Diluted (TTM)
−$0.94
+38.7% YoY Q1 May 2026
Gross Margin
99.5%
Q1 May 2026
Operating Margin
-219.1%
Q1 May 2026
Net Margin
-773.6%
Q1 May 2026
Free Cash Flow (TTM)
−$365.14M
Q1 May 2026
Cash
$205.19M
Q1 May 2026
Total Debt
$884K
Q1 May 2026
Shares Outstanding
1.05B sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings